Basilea Pharmaceutica Enters A Global Collaboration With Johnson & Johnson's (JNJ) Affiliate Cilag AG International (JNJ) For Basilea's Phase III, First-In-Class Antibiotic Ceftobiprole (BAL5788) 
10/19/2005 5:12:37 PM

BASEL, Switzerland, Feb. 3, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it has entered into an exclusive worldwide agreement with Cilag AG International, a Johnson & Johnson company, to develop, manufacture and market ceftobiprole, Basilea's novel broad-spectrum cephalosporin antibiotic that has activity against methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole is in phase III clinical trials in complicated skin and skin structure infections and hospital-acquired pneumonia trials are in preparation. Both indications have been granted fast track designation by the U.S. Food & Drug Administration.